chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient stated that a few days after receiving the shot she began feeling numb/tingling feelings in the arm, she also says that when she is at rest she gets a feeling like her arm is moving - she just wanted us to know since it is still happening a month after the vaccination, I asked patient for permission to report the reaction and filled out the form.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 26Jan2021 as dose 1, single (Lot number: EL9261), on 17Feb2021 as dose 2, single (Lot number: EN6200) and on 05Oct2021 as dose 3 (booster), single (Lot number: 30130BA) at the age of 61 years for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 04Apr2022 as dose 4 (booster), single (Lot number: 003K21-2A) for covid-19 immunisation. The patient's relevant medical history included: "Osteoporosis" (unspecified if ongoing); "Asthma" (unspecified if ongoing). Concomitant medication(s) included: ACETAMINOPHEN, start date: Dec2021; ALLER FLO, start date: Dec2021; ALENDRONATE SODIUM, start date: Mar2022. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "not recovered" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jun2022) Positive, notes: continue to test positive 16 days after my initial positive test. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Patient received Paxlovid from 06Jun2022 to 11Jun2022 as Covid-19 treatment. Other medication in two weeks included unspecified medication from Mar2022. Adverse event 3 days after completing Paxlovid, patient started having symptoms again. Patient was feeling better after 4 days, but never tested negative and continue to test positive 16 days after initial positive test.
Pt. is a 32 yo F with a PMHx of ADD who scheduled an urgent care visit on 3/23/2021 with complaints of Left chest wall pain and difficulty taking deep breaths that have progressively worsened over the past 1-2 days. She received a Moderna COVID vaccination by us on 3/20/2021. She noticed left arm soreness on the night of the vaccination. The left arm soreness improved as the left chest wall pain began to worsen. She also reports that she had itching and hives. These symptoms were relieved with OTC Benadryl. She also reports sinus congestion and PND with a mildly productive cough. She denies wheezing and only reports SOB due to difficulty/discomfort with deep breaths. She reported minimal to no imporvemnet in chest wall pain with OTC Tyelnol 650mg/Ibuprofen 800mg. She was given an injection of Toradol 30mg IM on 3/23/2021 without significant mprovement.
Patient received vaccine on 11/20/06 and developed reaction that night. Came back to pharmacy next day with symptoms of redness, pain and swelling from the left shoulder to elbow. Went to ER next day.
taking antibiotics for a UTI; This is a spontaneous report from a contactable consumer (patient) via the . A female patient of an unspecified age received the first dose of bnt162b2, via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Patient was scheduled to get the second dose of the vaccine on 15Apr2021. However, the patient is taking antibiotics for a UTI. She's taking this medicine for 5 days. Patient wants to know if she can take the vaccine while taking the antibiotics. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
Patient received multiple vaccines on 7/30/19 in March 2019. Patient was admitted to Hospital 8/2-8/25/19 for new diagnosis of mixed phenotype acute leukemia (B-myeloid, Philadelphia chromosome positive, CNS 2A). He received chemotherapy with IT cytarabine on 8/23 and vincristine and daunorubicin on 8/24. He was given IT methotrexate on 8/30 and noted to have rash on neck that was initially thought to be steroid induced acne. PCR testing of the lesion was positive for VZV. He was admitted again on 9/4 for fever and neutropenia and was started on empiric therapy with acyclovir on 9/5/19. Patient has recovered from infection and all lesions are scabbed over. He has also resumed chemotherapy
Side effects began about 14 hours after 2nd dose. Fever, extreme pain in back, legs, head and arm pits. Dizziness. Still experiencing side affects 30 hours later.
Traveler complained that after completing the final oral dose of typhoid he fell violently ill with stomach pain, fevers, diarrhea and night sweats. He said this went on for over a month and included oral thrush. He saw his PCP multiple times for these symptoms and was given multiple antibiotics and nystatin. Labs and stool studies were all negative. This was all prior to his travel.
20 minutes post vaccination, patient developed rash, hives, swelling in both arms, neck and eyes, and headache.  The patient did not report trouble breathing.  Patient was given 600 mg ibuprofen and 50 mg diphenhydramine
Information has been received on 19NOV2014 from a pharmacist regarding a 72 year old female with a medical history which included shingles (a year earlier), post-herpetic neuralgia (PHN), Parkinson's disease and asplenia. She was also reported to have allergies to intravenous dyes, Codeine and Tetanus. The pharmacist reported that on 18NOV2014 the patient received ZOSTAVAX (0.65ml subcutaneous) (Lot#/Expiration date K008895/20SEP2015) in her left posterior arm around 2:00PM. Concomitant medication included oxymorphine hydrochloride, CYMBALTA, gabapentin, diflunisal, and VESICARE. The patient notified the pharmacist around 6:00PM by telephone that she was "feeling well." The pharmacist reported that on the morning of 19NOV2014, she received a message from the patient, who said that she "can't move her body." The pharmacist called the patient around 9:00AM on 19NOV2014 and the patient was being taken by emergency medical transport services to an unspecified hospital's emergency department. The pharmacist notified the patient's healthcare provider, who was agreeable to follow-up for additional information. The pharmacist did not know if the patient was going to be admitted to the hospital or how severe her symptoms were. No additional information was provided. Additional information is expected.
Patient was vaccinated on 6/2/2015. Wednesday evening, after mowing his lawn and showering, he noticed itching and saw redness. Today (6/4/2015) at 12 PM, he said he noticed 3/4th inch of red, lumpy rash surrounded by about an inch of redness. Patient reports it is hot to the touch. He was instructed to tell us if the redness gets worse, and that Benadryl would be ok for the itching.
felt nauseated p/shot, ate lunch, vomited, has felt lightheaded & has pain in lt arm where shot was given, extending down into elbow;cont to feel nausea & lightheadedness 2hr p/shot;
Extreme itching at site. Red and swollen from shoulder to elbow for 10 days.
At 10:15 4/27/17 mom called MD on call to report fever 102.9, listlessness, and difficulty to awaken. Mom gave TYLENOL and sponge bath. After sponge bath and TYLENOL, patient was alert and attentive. Temp resolved by morning of 4/28/17 to 98.3. Patient was back to baseline.
Here at  booster clinic, first vaccine was J&J over 8 months ago. Today requested Pfizer for his booster. Within 10 minutes of the vaccination he developed nausea, lightheadedness, and chest tightness. Wheeled down to the ED from the vaccination clinic that was running.
After the 2 Moderna regular boosters she felt itchy and rash; After the 2 Moderna regular boosters she felt itchy and rash; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (After the 2 Moderna regular boosters she felt itchy and rash) and RASH (After the 2 Moderna regular boosters she felt itchy and rash) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     The patient had not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  The patient's past medical history included Leg injury. Previously administered products included for Product used for unknown indication: Johnson & Johnson vaccine (1st dose) on 08-Apr-2021. Past adverse reactions to the above products included No adverse event with Johnson & Johnson vaccine. Concurrent medical conditions included Asthma. Concomitant products included SALBUTAMOL (ALBUTEROL HFA), FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (WIXELA INHUB) and MONTELUKAST for Asthma.   On 10-Jan-2022, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-May-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2022, the patient experienced PRURITUS (After the 2 Moderna regular boosters she felt itchy and rash) and RASH (After the 2 Moderna regular boosters she felt itchy and rash). The patient was treated with PARACETAMOL (TYLENOL) in 2022 at an unspecified dose and frequency. At the time of the report, PRURITUS (After the 2 Moderna regular boosters she felt itchy and rash) and RASH (After the 2 Moderna regular boosters she felt itchy and rash) outcome was unknown.            It was reported that after the 2 Moderna regular boosters patient felt itchy and rash and took Tylenol.   This case was linked to MOD-2022-689226 (Patient Link).
Headache began day after. I also get migraines and initially thought it was a migraine but it did not respond to migraine medication. Taking advil and tylenol in addition to rizatriptan. Headache continues on Sunday 48 hours after vaccination.
This is one case out of a cumulative total of 229 cases solicited from the EDSS database during the surveillance period from 01 January 2010 to 14 July 2014. These 229 cases represent children who received 3 or more doses of Sanofi Pasteur vaccine; cases of pertussis disease in children who received DTaP combination vaccines from other manufacturers are not reported as per study protocol. Initial report received on 14 July 2014 from the investigator participating in a post-marketing study under the reference number M5A16. A case of pertussis disease in a 10 month old female subject (initials not reported) was identified by the investigator based on review of data from the Electronic Disease Surveillance (EDSS) electronic database. The subject had received three total doses of vaccine: one dose of DAPTACEL (lot number C4431AA) on 25 September 2013 and two doses of PENTACEL, on 18 December 2013 (lot number C4577AA) and 13 March 2014 (lot number C4660AB). Routes and sites of administration were not reported. The subject developed a cough and catarrhal illness on 15 June 2014, approximately 3 months after the last dose. She also experienced paroxysmal cough beginning 18 June 2014, pertussive vomiting, and sleep disturbance. Laboratory testing included positive PCR on 20 June 2014. Chest x-ray was negative for pneumonia. Corrective treatments consisted of Azithromycin starting on 21 June 2014 for 5 days. The subject was not hospitalized. At the time of final contact on 08 July 2014, the subject's cough had resolved. The duration of the subject's cough was reported at that time as 14 days. Investigator causality assessment is not required as per protocol. Upon internal review on 17 July 2014, doses 1 and 2 of DAPTACEL (administered 25 September 2013 and PENTACEL, administered 18 December 2013) were moved from suspect to product history. No new information was added to the case. Documents held by sender: None.
Patient booked his own 2nd dose appointment at our location.  His first dose was given at another facility on 3/2/21.  We informed him that the dose was a day early, but he said he needed to get it today.  Patient was given the second dose 3/29/21.
Vaccine recipient requested vaccine be administered in the abdomen. This was discovered after the vaccine was given.  1"synringe given LLQ
Influenza vaccine given in (R) deltoid on 2/26/16. Next day, had lymph node enlargement in axilla. Went to Occupational Health and treated with warm compresses. It was tender to touch and resolved on 3/5/16 completely.
Pt states on 15DEC91 pt 1st exp joint pain in ankles, progressing into hands, knees & hips; joints of the hand appear swollen; no reddness noted; (pt referred to pvt MD 20DEC91); pt seen by MD med given;
Rash, probably erythema multiforme, to face, trunk, back and extremities; with generalized erythematous urticarial rash with some target lesions.
This spontaneous report as received from a physician refers to a currently 15 month old patient of unknown gender. The patient's medical history and concurrent conditions were not reported. On an unknown date in February 2015, the patient was vaccinated with the first dose of VAQTA (route, anatomical location, lot# and expiration date were not reported). On an unknown date in May 2015, just 3 months after initial dose, the patient was inadvertently vaccinated with the second dose of VAQTA (route, anatomical location, lot# and expiration date were not reported). There was no concomitant therapy reported. No adverse effect reported. Additional information is not expected since the physician declined to participate in the adverse event collection process.
Information has been received from a registered pharmacist concerning a 12 month old male with a past medical history who on 6/2/04 was vaccinated with varicella virus vaccine live. There were no concomitant medication. On 6/3/04, the patient developed a croupy cough. The pediatrician prescribed the patient corticosteroid and azithromycin to treat the condition. No product quality complaint involved. At the time of the report, the patient had not recovered. Additional information has been requested.
Chills; Extreme fatigue; This is a spontaneous report from a contactable physician (sister in law). A 32-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 11Jan2021 at single dose for COVID-19 immunization.  The patient medical history and concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization and did not experienced adverse side effects. On 11Jan2021, the patient experienced chills and extreme fatigue (developed 12 hours after injection). The patient outcome of the events was recovered on 12Jan2021 (after a night of rest).  The information on the batch number has been requested.
Menstrual cycle was disrupted; This is a spontaneous report from a contactable nurse (patient). A 44-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration, administered in arm left on 12Jan2021 13:30 (at the age of 44 years old) (Batch/Lot number was not reported) as 2nd dose, single for COVID-19 immunisation. Medical history included depression and sacroiliitis, both from an unknown date; known allergies: Pcn (Penicillin) from an unknown date. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), escitalopram oxalate (LEXAPRO) and topiramate, all taken for an unspecified indication, start and stop date were not reported. The patient previously took erythromycin and experienced allergies. The patient previously received first vaccination of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), on 22Dec2020 02:15 PM at left arm for COVID-19 immunisation. The patient was not pregnant. It was reported that after second vaccine, on 20Jan2021 12:00 AM, the patient experienced that her menstrual cycle was disrupted and she had another full cycle one week later. This has never happened as she was usually very regular to the day. No treatment was provided. Further reported that patient has no COVID prior vaccination, no COVID test post vaccination. The outcome of the event was recovered on unspecified date in 2021.  No follow-up attempts are possible; Information about lot/batch number cannot be obtained.
Nothing for the first two hours; malaise and fatigue from hours 2-8 post-vaccination, with a return to vibrancy around 1500 local time. Around 1700, fatigue returned. Took a 3 mile walk between 1700-1800. Consumed two beers @ 7% ABV between 1800-1845. Around 1830 began feeling tingling, chills and muscle and joint pain which continues. The pain is similar to DOMS that occurs after a robust workout; did not have a robust workout today. I'm fully functional, able to eat and able to otherwise function, so the symptoms are manageable.
Pt was given the vaccine and it was not yet approved for her age. She did not have any problems, side effects, or issues but she was notthe recommended age for administration. Her mother was notified and she does want her to get the second dose. Waiting for guidance from Moderna on recommendation.
A week later red rash and welt, started Wednesday and continues to grow. Was not there till Wednesday a week later.
This vaccine expired 8/4/2023, 5 days before it was administered. The patient has not experienced any adverse side effects.
This spontaneous report was received from a registered nurse concerning a patient of unknown age and gender. The patient's concurrent conditions and medical history was not provided. On 31-OCT-2016, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 lot # M005287, expiration date 08-OCT-2017, (strength, dose and route were not provided), which was exposed to 8.6 Celsius Degrees for 25 minutes. It was reported that the vaccine was previously exposed to a temperature of 8.1 Celsius Degrees for 5 minutes. The temperature excursion was detected by a data logger. There were no concomitant medications and adverse effects reported. No product quality complaint was involved. Additional information has been requested.
Bilateral axilla rash, and rash bilateral upper chest ~ 1 hour after vaccine.
This is a spontaneous report from a contactable physician through a Pfizer sales representative. A 65-year-old female patient received PREVNAR 13 twice. First dose of PREVNAR 13 was given on 14Jan2016 and the second one was given on 24Sep2018, both at single dose, for immunization. The patient's arm got sore on an unknown date in 2018. Outcome of the event was unknown. Physician considered that patient's arm got sore because the way the immunization was given to her, not the immunization. The information on the lot number has been requested. Follow-up (22Oct2018): New information received from a contactable physician includes:events updated (arm got sore added). No follow-up attempts are possible, information about batch number cannot be obtained.
pt recv vax 19APR97 lt deltoid on 22APR97;noted fluid-fill blister @ inj site;spread to body on 24APR97 + for varicella virus;
Found dead in bed by paternal grandmother 18MAR94; CPR performed by EMT's without success; autopsy performed: cause of death: disseminated viral infection (respiratory, renal, and gastrointestinal);
Information has been received from a registered nurse regarding multiple unspecified patients of unknown age and gender. On an unknown date the patients were vaccinated with improperly stored M-M-R II (lot # K026366, expiration date 15-DEC-2016; lot # K007982, expiration date 03-JUN-2016; lot # K008198, expiration date K008198; lot # K007106, expiration date 16-MAY-2016, route not provided). No adverse events were reported. Product quality complaint was not involved. This is one of the several reports from the same reporter. Additional information has been requested.
Excruciating pain. no relief! Dr injected cortisone, no relief!  Tried massage therapy(worse pain), X-rays (pinched nerve) no relief! Referred to Pain Management (steroid oral) short relief time! Referred to Doctor July 1, (epidural injection) finally some relief! Had EMG (ulnar tunnel syndrome) ! Had two more epidurals from Doctor ( pain relief! Massage therapy (nerve damage) on numb arm and hand, relief was intermittent! Still dealing with numbness that aches!
Pt reports within a week after second dose of Moderna, he began having increased heart rate, wheezing when laying flat, and fatigue which has persisted from April 2021 until present.
Blood clot; Elevated blood pressure; This is a spontaneous report from a contactable consumer (patient). A 50-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), intramuscular on 15Sep2021 (Batch/Lot Number: FE3592) (at the age of 50-years-old) as dose number unknown, single for COVID-19 immunisation. The patient has no relevant medical history and there were no concomitant medications. The patient had no prior vaccination (within four weeks). On an unspecified date in Sep2021, the patient reported possible blood clot and elevated blood pressure after receiving the COVID shot and said she was going to the emergency room. The outcome of the events was not recovered.  No follow-up attempts are possible. No further information is expected.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 62-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 28Sep2022 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 62 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 18Feb2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 18Mar2021 as dose 2, single (Batch/Lot number: unknown), in left arm, on 10Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm and on 20Jul2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "high cholesterol" (unspecified if ongoing). Concomitant medication(s) included: ROSUVASTATIN, start date: Jul2022, stop date: 15Dec2022; MONTELUKAST, start date: May2014. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 28Sep2022, outcome "not recovered"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (21Dec2022) Negative, notes: 2 days after completing Paxlovid treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19. Patient had no known allergies. Patient was treated with Paxlovid on 14Dec2022 to 18Dec2022 for COVID-19. Covid symptoms mostly cleared and tested negative 2 days after completing Paxlovid treatment.   The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
1620/Vaccine administered of 0.3 mL of Purple top Pfizer was administered to 9 y/o pt. Pt was observed for an additional 15 min for a total of 30 min. Pt showed no signs or symptoms of distress or anaphylaxis. The pt's father was educated of possible side effects such as fever, muscle pain, nausea and other flu like symptoms. Father was instructed to treat symptoms with Tylenol or Ibuprofen as necessary, and seek further medical treatment if symptoms remained uncontrolled. Father verbalized understanding of education, and went to seek further care. Father had no additional questions or concerns at time of departure from unit.
Patient called and mentioned that he has lingering pain/soreness on his right arm after more than a week of getting his 2nd dose of Covid vaccine. He had his shot on his left arm. He said that he had some swelling also on his arm after his 1st dose but waited until his 2nd dose to inform us.